Wegovy BMI Requirements vs Mounjaro Eligibility Criteria
Both Wegovy and Mounjaro share identical BMI requirements under UK licensing regulations, making your choice dependent on clinical factors rather than eligibility differences. The MHRA-approved criteria specify BMI ≥30 kg/m², or BMI ≥27 kg/m² with at least one weight-related comorbidity such as type 2 diabetes, hypertension, or sleep apnoea. Adolescents aged 12 years and older with body weight exceeding 60kg may also qualify if their BMI corresponds to ≥30 in adults. This unified approach means that meeting Wegovy BMI requirements automatically qualifies you for Mounjaro consideration, and vice versa.
The key differentiator lies not in eligibility but in mechanism of action and dosing convenience. Wegovy (semaglutide) works as a GLP-1 receptor agonist, mimicking natural fullness hormones to reduce appetite and promote satiety after smaller meals. Mounjaro (tirzepatide) employs a dual approach, targeting both GIP and GLP-1 receptors for potentially enhanced metabolic effects. Both require prescription oversight and must be used alongside lifestyle modifications, ensuring that Wegovy BMI requirements and Mounjaro eligibility serve as starting points rather than ensures of treatment success.
Pricing Comparison: Wegovy BMI Requirements and Mounjaro Costs
Understanding the financial commitment for both treatments helps you plan your weight management journey effectively. Wegovy follows a 5-dose escalation schedule starting at £79.99 for the initial 0.25mg dose (weeks 1-4), progressing through £94.99 for 0.5mg, £99.99 for 1mg, £139.99 for 1.7mg, and reaching £209.99 for the 2.4mg maintenance dose. Our Intro Duo bundle combines the first two doses for £169.99, whilst the Ultimate Stability Trio provides three months of maintenance therapy for £649.99. New customers apply code FIRST40 at checkout, and returning customers use DOSE25 to access these competitive rates.
Mounjaro pricing follows a similar progression but with six dose levels, starting from the same £79.99 entry point but extending through 2.5mg, 5mg, 7.5mg, 10mg, 12.5mg, and 15mg options. This extended range may offer more titration flexibility for patients requiring gradual dose adjustments. Both treatments qualify for our next-day cold-chain delivery service, ensuring temperature integrity throughout transport. The identical starting costs mean that initial Wegovy BMI requirements assessment and Mounjaro evaluation carry the same financial entry point, with long-term costs depending on your optimal maintenance dose.
Clinical Evidence Supporting Wegovy BMI Requirements
The STEP clinical trial programme provides robust evidence supporting current Wegovy BMI requirements and treatment outcomes. In the landmark STEP 1 trial (Wilding et al., NEJM, 2021), patients taking Wegovy alongside a reduced-calorie diet and increased physical activity achieved approximately 15% average weight loss at 68 weeks, compared to 2.4% with placebo. STEP 5 demonstrated sustained weight management with 15.2% average loss maintained at two years, whilst STEP 3 showed enhanced outcomes of approximately 16% when combined with intensive behavioural therapy.
The recent SELECT cardiovascular outcomes trial revealed a 20% reduction in major adverse cardiovascular events (HR 0.80), supporting broader health benefits beyond weight management. These findings reinforce why Wegovy BMI requirements focus on patients with existing weight-related health risks, as the medication may help address multiple comorbidities simultaneously. However, individual results vary, and these trial outcomes represent averages across diverse patient populations rather than assured individual outcomes.
How Wegovy Works: GLP-1 Mechanism for BMI Requirements
Wegovy functions as a GLP-1 receptor agonist, mimicking the action of glucagon-like peptide-1, a naturally occurring hormone that regulates appetite and glucose metabolism. When administered via the once-weekly FlexTouch injection, semaglutide binds to GLP-1 receptors in the brain's appetite control centres, promoting feelings of fullness and reducing food cravings between meals. This mechanism explains why Wegovy BMI requirements target patients with elevated BMI, as the medication works most effectively in individuals with disrupted appetite regulation and metabolic dysfunction. The treatment also slows gastric emptying, prolonging satiety after eating and supporting portion control efforts. Additionally, GLP-1 receptor activation may influence reward pathways in the brain, potentially reducing cravings for high-calorie foods and supporting long-term dietary behaviour changes essential for sustained weight management success.
Streamlined Ordering Process for Both Treatments
Our efficient ordering system accommodates both Wegovy BMI requirements assessment and Mounjaro evaluation through a comprehensive 3-minute online clinical questionnaire. This assessment covers your medical history, current medications, weight management goals, and any relevant comorbidities that support prescription approval. Once submitted, our qualified prescribers review your information within three working days (or 24 hours with express service), ensuring thorough clinical oversight for these prescription-only medicines. Upon approval, your chosen treatment ships via next-day delivery using specialised cold-chain packaging that maintains the required 2-8°C temperature throughout transit. Our GPhC-registered pharmacy (#9012878) ensures full regulatory compliance and pharmaceutical-grade storage conditions from our facility to your door.
Storage and Practical Considerations
Both treatments require refrigeration at 2-8°C before first use, but Wegovy offers superior travel convenience with 6 weeks of room temperature stability compared to Mounjaro's 21-day limit. This extended stability makes Wegovy particularly suitable for patients with active lifestyles, frequent travel, or inconsistent refrigeration access. The FlexTouch pen design provides user-friendly injection with clear dose windows and intuitive operation, whilst the mandatory dose escalation schedule ensures gradual tolerance development. Both medications arrive with comprehensive patient information leaflets and injection technique guidance. The prescription-only status requires ongoing prescriber oversight, with regular review appointments recommended to monitor progress and adjust treatment plans as needed throughout your weight management journey.
BMI Requirements and Long-term Treatment Planning
Meeting initial Wegovy BMI requirements represents just the beginning of a comprehensive weight management strategy that may extend for months or years. The STEP 1 extension study revealed that patients regained approximately two-thirds of lost weight within one year of stopping treatment, emphasising the chronic nature of weight management and the importance of sustained therapy. This pattern reinforces why both Wegovy and Mounjaro BMI requirements focus on patients with significant metabolic disruption rather than cosmetic weight concerns. Long-term success depends on integrating medication with permanent lifestyle changes, including sustainable dietary modifications and regular physical activity.
Your prescriber will regularly reassess whether continued treatment remains appropriate based on weight loss response, side effect tolerance, and overall health improvements. The 2.4mg Wegovy maintenance dose or equivalent Mounjaro level should be viewed as long-term commitments rather than short-term interventions. Planning for extended treatment helps establish realistic expectations and ensures adequate financial preparation for ongoing therapy costs throughout your weight management journey.
Expert Prescriber Guidance and Treatment Selection
Choosing between Wegovy and Mounjaro involves clinical considerations beyond basic BMI requirements, requiring expert prescriber evaluation of your individual circumstances. Factors such as diabetes status, cardiovascular risk profile, gastrointestinal tolerance, and previous weight management attempts influence treatment selection more than eligibility criteria alone. Our qualified prescribers assess these variables alongside your personal preferences regarding injection frequency, storage requirements, and dose escalation timelines. The availability of both treatments through EverydayMeds ensures that clinical recommendations drive your choice rather than supply constraints or limited options. Whether your prescriber recommends Wegovy's established GLP-1 approach or Mounjaro's innovative dual mechanism, our pharmacy provides the same high-quality service and pharmaceutical expertise. Apply code FIRST40 for new customers or DOSE25 for returning patients at checkout to access competitive pricing on whichever treatment best suits your clinical profile and weight management goals.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026